StockData

Agenus vs Autolus Therapeutics

AGEN and AUTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and AUTL compare

Agenus and Autolus Therapeutics are about the same size, with market caps of $303M and $303M.

Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 30.5% for Agenus).

Autolus Therapeutics scores higher on the StockData Score (5 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENAUTL
Size and price
Market cap$303M$303M
Share price$6.73$1.14
Change, 1 year51.9%−10.9%
Change, 5 years−90.4%−81.8%
Beta (5Y)–3.40
Employees81754
StockData Score
Total score35 (better)
Valuation score11
Growth score23 (better)
Performance score00
Health score01 (better)
Dividend score00
Valuation
P/S2.3× (better)2.6×
P/B–4.1×
EV/EBITDA7.5×–
FCF yield−32.5% (better)−76.7%
Fair value–$1.41
Margin of safety–19.3%
Growth
Revenue growth (TTM)30.5%292% (better)
Revenue growth, 5Y average5.3%–
Profitability
Gross margin99.5% (better)15.7%
Operating margin27.3% (better)−211%
Net margin–−239%
FCF margin−74.2% (better)−198%
Return on equity–−133%
Financial health
Net debt / EBITDA0.28–
Interest coverage0.6× (better)−5.9×
Current ratio0.344.89 (better)
Altman Z-score−16.50−4.58 (better)
Piotroski F-score–2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%49.7%
Held by insiders6.6%24.6%
Insider net buying, 12 months–−$15.7K
Short interest, % of float18.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.